Literature DB >> 3265775

The incidence of vision loss in a diabetic population.

S E Moss1, R Klein, B E Klein.   

Abstract

The 4-year incidence of blindness and vision loss was examined in a population-based study of diabetes mellitus. In subjects participating in baseline and 4-year follow-up examinations, the rate of blindness was 1.5, 3.2, and 2.7% in younger onset persons, older onset persons taking insulin, and older onset persons not taking insulin, respectively. The rate of blindness increased with increasing age, increasing diabetic retinopathy severity, and lower baseline visual acuity in all three groups. Blindness increased with increasing duration of diabetes in younger onset persons and older onset persons taking insulin. The incidence of vision loss, as measured by a doubling of the visual angle, was associated with older age, more severe retinopathy, and presence of macular edema in the three groups. It was also associated with duration of diabetes, presence of proteinuria, and higher glycosylated hemoglobin in younger onset and older onset persons taking insulin.

Entities:  

Mesh:

Year:  1988        PMID: 3265775     DOI: 10.1016/s0161-6420(88)32991-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  44 in total

1.  Growth factors/chemokines in diabetic vitreous and aqueous alter the function of bone marrow-derived progenitor (CD34⁺) cells in humans.

Authors:  Sankarathi Balaiya; Maria B Grant; Joshua Priluck; Kakarla V Chalam
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-26       Impact factor: 4.310

2.  The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy.

Authors:  Ronald Klein; Kristine E Lee; Ronald E Gangnon; Barbara E K Klein
Journal:  Ophthalmology       Date:  2009-10-31       Impact factor: 12.079

3.  Vessel diameter study: intravitreal vs posterior subtenon triamcinolone acetonide injection for diabetic macular edema.

Authors:  M M Kurt; O Çekiç; Ç Akpolat; M Aslankurt; M Elçioğlu
Journal:  Eye (Lond)       Date:  2017-03-24       Impact factor: 3.775

Review 4.  Impact of diabetic retinopathy screening on a British district population: case detection and blindness prevention in an evidence-based model.

Authors:  M O Bachmann; S J Nelson
Journal:  J Epidemiol Community Health       Date:  1998-01       Impact factor: 3.710

5.  Maculopathy in patients with diabetes mellitus type 1 and type 2: associations with risk factors.

Authors:  E Zander; S Herfurth; B Bohl; P Heinke; U Herrmann; K D Kohnert; W Kerner
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

6.  Pretreatment of posterior subtenon injection of triamcinolone acetonide has beneficial effects for grid pattern photocoagulation against diffuse diabetic macular oedema.

Authors:  Masahiko Shimura; Toru Nakazawa; Kanako Yasuda; Takashi Shiono; Kohji Nishida
Journal:  Br J Ophthalmol       Date:  2006-10-31       Impact factor: 4.638

7.  [Diagnosis, therapy and follow up of diabetic eye disease].

Authors:  Michael Stur; Stefan Egger; Anton Haas; Gerhard Kieselbach; Stefan Mennel; Reinhard Michl; Michael Roden; Ulrike Stolba; Andreas Wedrich
Journal:  Wien Klin Wochenschr       Date:  2012-12       Impact factor: 1.704

8.  Ultrastructural alterations in capillaries of the diabetic hypertensive rat retina: protective effects of ACE inhibition.

Authors:  A A Dosso; E Rungger-Brändle; P M Leuenberger
Journal:  Diabetologia       Date:  2004-07-09       Impact factor: 10.122

Review 9.  Clinical practice guidelines for treatment of diabetes mellitus. Expert Committee of the Canadian Diabetes Advisory Board.

Authors: 
Journal:  CMAJ       Date:  1992-09-01       Impact factor: 8.262

10.  Changes in visual impairment prevalence by period of diagnosis of diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy.

Authors:  Ronald Klein; Kristine E Lee; Michael D Knudtson; Ronald E Gangnon; Barbara E K Klein
Journal:  Ophthalmology       Date:  2009-07-18       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.